You are here

Oligonucleotide Inhibition for cardiac regeneration in Ischemia

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41HL134387-01A1
Agency Tracking Number: R41HL134387
Amount: $225,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NHLBI
Solicitation Number: PA16-303
Solicitation Year: 2016
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-04-01
Award End Date (Contract End Date): 2018-09-30
Small Business Information
La Jolla, CA 92037-2933
United States
DUNS: 079805635
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 (858) 869-3564
Business Contact
Phone: (858) 869-3564
Research Institution
9500 Gilman Drive, Mail Code 0934
LA JOLLA, CA 92093-0934
United States

 Nonprofit College or University

Ischemic heart disease IHD is the single largest cause of death worldwide A heart attack or myocardial
infarction MI results from limitation of coronary blood flow to the heart causing ischemia and ultimately
irreversible death of cardiomyocytes The size of a myocardial infarct correlates with the degree of deterioration
of heart function compromise of contractile reserve and overtime the likelihood of mortality from heart failure
HF Prompt restoration of arterial perfusion with thrombolytic and antiplatelet therapy during percutaneous
coronary intervention has led to a decline in acute mortality from MI However the prevalence of HF among
survivors has augmented because irreversible cardiomyocyte death results in a residual inducible ischemia and
permanent scarring A major pathologic problem is the failure of human adult cardiomyocytes to regenerate
themselves endogenously following a MI This is compounded by a lack of adjunctive treatments pharmacologic
or cellular that can be administered in conjunction with reperfusion or after to stimulate regeneration of heart
muscle Effective promotion of endogenous cardiomyocyte regeneration in the ischemic heart with concomitant
reduction of scar size would potentially offer a powerful new treatment of MI and its adverse pathophysiologic
consequences Inhibition of a specific combination of four MicroRNAs miR miR miR let a and let c
is a critical regulator of cardiomyocyte dedifferentiation and heart regeneration in zebrafish The sequences and
target proteins of these miRs are conserved in humans In vivo adeno associated virus AAV delivery of
inhibitors of these miRs into the hearts of mice with left coronary artery ligation increases the expression of the
beta subunit of farnesyl transferase and SWI SNF related matrix associated actin dependent regulator of
chromatin subfamily a member Cardiac regeneration was confirmed by the expression of proliferation and
cytokinesis markers labeled uridine incorporation into DNA together with scar tissue regression and heart
functional improvement A disadvantage of viral delivery is the high prevalence of anti AAV antibodies in humans
that could neutralize their effect As an alternative JAAN Biotherapeutics will investigate whether two synthetic
specific potent and nuclease resistant nucleic acid miR inhibitors anti miRs to miR and let a c can
reduce ischemic injury in an experimental murine model of ischemic reperfusion and constitute an innovative
approach to regenerate human cardiomyocytes The research in Phase I will define whether the anti miRs
proliferate normal heart muscle provide information on an effective dose and sustainability of effect and
establish any proliferative or off target side effects in remote tissues Aim Aim will study whether the anti
miRs administered after a min cardiac ischemic injury in mice either at the time of reperfusion or days after
ischemia can reduce scar size increase cardiac function and regenerate cardiac muscle Aim will provide
safety information and Aim is critical to confirm efficacy of the anti miRs in the murine ischemic heart These
studies are pivotal for future preclinical and clinical study design PROJECT NARRATIVE
The proposal s objective is to develop a therapy that can be given to patients shortly after a heart attack to
improve their long term outcome and prevent heart failure the single largest cause of death in the world The
academic partner has developed mouse models of ischemic heart disease and methods that provide precise
three dimensional visualization and quantification of heart damage and function The small business partner is
studying an innovative ribonucleic acid interference technology that regenerates damaged cardiac muscle by
reactivating an evolutionary conserved process In partnership we intend to test whether two synthetic
ribonucleic nucleic acid inhibitors regenerate heart muscle without side effects and can reduce the
pathophysiology of cardiac ischemic injury in mice Information on the dose sustainability of effect and timing of
administration to regenerate heart muscle will enable the design of future safety toxicology studies potentially
allowing clinical development that may improve the long term outcome for patients with ischemic heart disease

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government